Clinical trials: Resectable Non-Small-Cell Lung Cancer
Non-small Cell Lung Cancer, Radiation Therapy
Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma
The purpose of this study is to establish on the market and to clinically evaluate a new strategy of treatment for patients with locally advanced non-small cell lung cancer using deformable repositioning of 4D imaging.
- Conditions
- Non-small Cell Lung Cancer, Radiation Therapy, Locally Advanced Disease, Non-metastatic Disease
- Trial name
- midP (NCT01635270)
- Testing
- mid-position radiation strategy, ITV
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Centre Leon Berard
Resectable Colon Cancer, Resectable Non-small Cell Lung Cancer
Mechanism of Action Trial of ColoAd1
To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour tissue when administered by intra-tumoural injection or within colon, non-small cell lung, bladder and renal cell tumour tissues following…
- Conditions
- Resectable Colon Cancer, Resectable Non-small Cell Lung Cancer, Resectable Bladder Cancer, Resectable Renal Cell Carcinoma
- Trial name
- MOA (NCT02053220)
- Testing
- Colo-Ad1
- Where
- 2 sites in Spain
- Volunteers
- 17 people
- Sponsor
- Akamis Bio
Non-Small Cell Lung Cancer - Completely Resectable
DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer
To determine if a vaccine made from patient's own tumor tissue can stimulate an immune response against the patient's tumor cells. To determine the safety of the vaccine
- Trial name
- NCT00298298
- Testing
- L-Vax: Autologous, DNP-Modified NSCLC Vaccine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- AVAX Technologies
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)